NPPB and Miyoshi myopathy: Our study is one of the first to prospectively evaluate NT-proBNP and hsTropI as cardiac biomarkers in newly diagnosed MM, in the purely high risk patient population of the multi-center GMMG-CONCEPT trial undergoing Isa-KRd treatment.